News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Webcasts December 16, 2025
Webcast: M&A Insights: Antitrust Clean Teams, State “HSR” Laws, and Lessons from Activision II
Join us for a half-hour recorded briefing covering several M&A practice topics. The webcast is part of a series of …
Firm News December 15, 2025
Gibson Dunn Advised CenterOak Partners and Turf Masters Brands on Sale of Turf Masters Brands
Gibson Dunn advised CenterOak Partners LLC and Turf Masters Brands, Inc. on the sale of Turf Masters Brands in a transaction with ExperiGreen Lawn Care
Firm News November 4, 2025
Gibson Dunn Advised SM Energy on $12.8 Billion Merger with Civitas Resources
Gibson Dunn advised SM Energy Company on its definitive, all-stock merger agreement with Civitas Resources, Inc
Firm News October 21, 2025
Gibson Dunn Advises CenterPoint Energy on the Sale of Vectren Energy Delivery of Ohio to National Fuel Gas Company for $2.62 Billion
Gibson Dunn is advising CenterPoint Energy, Inc. on the sale of its Ohio natural gas LDC business, Vectren Energy Delivery of Ohio, to National Fuel Gas Company for $2.62 billion
Firm News September 11, 2025
Gibson Dunn Advises Technip Energies on $556 Million Acquisition of Ecovyst’s Advanced Materials & Catalysts
Gibson Dunn is advising Technip Energies on its $556 million acquisition of Ecovyst Inc.’s Advanced Materials & Catalysts business
Firm News September 8, 2025
Gibson Dunn Advises SpaceX on $17 Billion Acquisition of EchoStar’s Full Portfolio of AWS-4 and H-block Spectrum Licenses
Gibson Dunn is advising SpaceX on its $17 billion acquisition of EchoStar’s full portfolio of AWS-4 and H-block 50 MHz spectrum licenses, along with certain international rights and priorities related to that spectrum.
Firm News September 4, 2025
Gibson Dunn Advises Arrowhead Pharmaceuticals on Global Licensing and Collaboration Agreement with Novartis
Gibson Dunn is advising Arrowhead Pharmaceuticals on its global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical-stage siRNA therapy targeting alpha-synuclein for the treatment of synucleinopathies, as well as for additional collaboration targets utilizing Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform
Firm News August 7, 2025
Gibson Dunn Advises Aris Water Solutions on Its Sale to Western Midstream Partners for Approximately $2 Billion
Gibson Dunn is advising Aris Water Solutions (NYSE: ARIS) on its sale to Western Midstream Partners (NYSE: WES) for approximately $2 billion